CD274 and neoplasm: The use of DLNM allows for targeted delivery of the CRISPR/Cas enzyme to tumor cell, enabling gene editing to disrupt PD-L1 expression and facilitate controlled release, ultimately leading to safe and effective immunotherapy activation.